近日,来自美国哈佛大学麻省总医院的Justin F. Gainor教授在Cancer Discovery杂志上发表文章T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603...
近日,来自美国哈佛大学麻省总医院的Justin F. Gainor教授在Cancer Discovery杂志上发表文章T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study。本研究描述mRNA-4157(V940)是一种个体化新抗原疗法,可靶向多达34种...
肝细胞癌(HCC)是全球最常见的癌症之一，它的死亡率在全球范围内呈上升趋势，2020年全球共有90.57万人诊断为肝癌，死亡患者达到83.02万。2023年11月，艾博生物宣布，与臻知医学联合启动肿瘤抗原mRNA治疗性疫苗ABOR2014注射液（IPM511）首次人体临床试验。研究旨在评估IPM511单药及联合PD-1抑制剂治疗经一线标准治疗病...
4. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial | Nature Medicine 5. Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with...
5. Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer | BioSpace 6. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer | Nature...
Moderna在2019ASCO重磅发布mRNA个性化癌症疫苗“mRNA-4157”1期临床研究的中期 数据 APExBIO 第55届美国临床肿瘤学会(ASCO)年会于2019年5月31日至6月4日在美国芝加哥召开。本次会议吸 引丕界3万8千名肿瘤专家参与。 6月3日,Moderna公司在2019年美国临床肿瘤学会(ASCO)年会 上发表了用于治疗实体瘤的mRNA-4157的1...
Hou P,Sehgal V,Chen X,Morrissey M,Daghestani HN,Feldman I,Srinivasan L,Frederick JP,Brown M,Aanur P,Meehan R,Burris HA.T Cell Responses to Individualized Neoantigen Therapy mRNA-4157(V940)Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study.Cancer Discov.2024 Aug 8...
Zaks T. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024 Jan 18:S0140-6736(23)02268-7. doi: 10.1016/S0140-6736(23)02268-7IF: 168.9 Q1 . Epub ahead of print...
Zaks T. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024 Jan 18:S0140-6736(23)02268-7. doi: 10.1016/S0140-6736(23)02268-7IF: 168.9 Q1 . Epub ahead of print...
This report includes updates from the mRNA-4157 Phase1(P1) study. The initial data was presented at ASCO2019. Methods This study evaluates the safety and efficacy of mRNA-4157 as monotherapy in patients with resected solid tumors (Part A) and in combination with pembrolizumab in patients with ...